Physician profile
David H Breen
NPI 1285662361
$7,592.22
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $869 · 2021: $1,196 · 2022: $1,780 · 2023: $2,261 · 2024: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,074.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,997.33 | 2019-2024 | Trelegy Ellipta, Nucala, Shingrix |
| Novo Nordisk INC | $1,733.52 | 2019-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,400.16 | 2021-2024 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $667.03 | 2022-2024 | Vraylar |
| Gilead Sciences, INC. | $380.31 | 2022-2023 | Epclusa |
| Supernus Pharmaceuticals, INC. | $313.59 | 2021-2024 | Qelbree, Qelbree |
| Pfizer INC. | $271.97 | 2023-2024 | |
| Galvanize Therapeutics, INC | $148.65 | 2023 | Aliya System |
| Corium, LLC | $126.00 | 2022-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $106.31 | 2019-2022 | |
| Tris Pharma INC | $84.48 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $73.74 | 2022 | |
| Lilly USA, LLC | $54.54 | 2024 | Jardiance |
| Neos Therapeutics, LP | $39.05 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.58 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $33.92 | 2019-2023 | Jornay Pm |
| Adlon Therapeutics L.P. | $31.68 | 2020 | |
| Mylan Specialty L.P. | $27.32 | 2024 | Yupelri |
| Shire North American Group INC | $25.82 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.02 | 2019 | |
| Pharming Healthcare, INC. | $18.20 | 2023 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Breen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.